PHS
RCUS icon

PFM Health Sciences’s Arcus Biosciences RCUS Stock Holding History

PFM Health Sciences’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-237,300
Closed -$6.16M – 105
2020
Q4 		$6.16M Sell
237,300
-2,700
-1% -$65.4K 0.22% 77
2020
Q3 		$4.11M Buy
+240,000
New +$5.36M 0.19% 71

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PFM Health Sciences's RCUS Position: Q4 2023 in Review

PFM Health Sciences sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 1,405,056 shares — an estimated $25.2M sold.

PFM Health Sciences first reported a position in RCUS in Q1 2018 and held it in 19 quarters. The position peaked at $139M in Q4 2021. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

  • PFM Health Sciences reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
  • PFM Health Sciences sold 1,405,056 Arcus Biosciences shares in Q4 2023, an estimated $25.2M.
  • PFM Health Sciences first reported a position in Arcus Biosciences in Q1 2018 and held it in 19 quarters.
  • PFM Health Sciences's Arcus Biosciences position peaked at $139M in Q4 2021.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on PFM Health Sciences's 13F filing for Q4 2023, filed 14 Feb 2024.